• shareshare
  • link
  • cite
  • add
auto_awesome_motion View all 2 versions
Other research product . 2020

Corticosteroids for patients with acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials

Mammen MJ. Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA;
Open Access
Published: 18 Mar 2020

Introduction: Acute respiratory distress syndrome (ARDS) is a rapidly progressing inflammatory lung disease with a high mortality rate without specific pharmacological therapy. Objective: We conducted a systematic review and meta-analysis on corticosteroid use in ARDS. Methods: A search of four medical literature databases was conducted. We retained randomized trials (RCTs) of corticosteroids in hospitalized adults with ARDS in a search up to February, 2020. Two reviewers identified eligible studies, independently extracted data, and assessed risk of bias. Authors assessed the certainty of the evidence using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Results: We included seven RCTs (n=851 patients). Corticosteroids reduced all-cause mortality (risk ratio [RR] 0.75, 95% CI: 0.59 to 0.95, p=0.02, moderate certainty) and duration of mechanical ventilation (mean difference [MD] -4.93 days, 95% CI: -7.81 days to -2.06 days, p<0.001, low certainty), and increased ventilator-free days (VFD) (MD 4.28 days, 95% CI: 2.67 days to 5.88 days, p<0.001, moderate certainty), when compared to placebo. Corticosteroids also increased the risk of hyperglycemia (RR 1.12%, 95% CI: 1.01 to 1.24, p=0.03, moderate certainty), and the effect on neuromuscular weakness was unclear (RR 1.30, 95% CI 0.80 to 2.11, p=0.28, low certainty). Corticosteroids for patients with acute respiratory distress syndrome: a rapid update systematic review and meta-analysis of randomized trials. Conclusions: These results suggest that systemic corticosteroids may potentially improve mortality, ventilator duration, and VFD in patients with ARDS. However, the studies included different corticosteroid classes and initiated the corticosteroid doses at different times, as well as different dosing regimens. Thus caution in the actual clinical application of these results is recommended.

33 references, page 1 of 4

1. Force ADT, Ranieri V, Rubenfeld G, et al. Acute respiratory distress syndrome. JAMA. 2012;307:2526-33.

2. Lewis SR, Pritchard MW, Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev. 2019;7:CD004477.

3. Maca J, Jor O, Holub M, et al. Past and Present ARDS Mortality Rates: A Systematic Review. Respir Care. 2017;62:113-22.

4. Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267-76.

5. National Heart L, Network BIARDSCT. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. New England Journal of Medicine. 2006;354:1671-84.

6. Tomashefski Jr JF. Pulmonary pathology of acute respiratory distress syndrome. Clinics in chest medicine. 2000;21:435-66. [OpenAIRE]

7. Sun S, Liu D, Zhang H, et al. Effect of different doses and time‑ courses of corticosteroid treatment in patients with acute respiratory distress syndrome: A meta‑ analysis. Exp Ther Med. 2019;18:4637-44.

8. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

9. Akl EA, Sun X, Busse JW, et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. Journal of clinical epidemiology. 2012;65:262-7.

10. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105-14. [OpenAIRE]

Related to Research communities
Download fromView all 2 sources